The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) show cardiovascular protective effects, regardless of the patient’s history of diabetes mellitus (DM). SGLT2is suppressed cardiovascular adverse events in patients with type 2 DM, and furthermore, SGLT-2is reduced the risk of worsening heart failu...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/14/2/141 |
_version_ | 1797297727694962688 |
---|---|
author | Ayami Naito Yuji Nagatomo Akane Kawai Midori Yukino-Iwashita Ryota Nakazawa Akira Taruoka Asako Takefuji Risako Yasuda Takumi Toya Yukinori Ikegami Nobuyuki Masaki Yasuo Ido Takeshi Adachi |
author_facet | Ayami Naito Yuji Nagatomo Akane Kawai Midori Yukino-Iwashita Ryota Nakazawa Akira Taruoka Asako Takefuji Risako Yasuda Takumi Toya Yukinori Ikegami Nobuyuki Masaki Yasuo Ido Takeshi Adachi |
author_sort | Ayami Naito |
collection | DOAJ |
description | Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) show cardiovascular protective effects, regardless of the patient’s history of diabetes mellitus (DM). SGLT2is suppressed cardiovascular adverse events in patients with type 2 DM, and furthermore, SGLT-2is reduced the risk of worsening heart failure (HF) events or cardiovascular death in patients with HF. Along with these research findings, SGLT-2is are recommended for patients with HF in the latest guidelines. Despite these benefits, the concern surrounding the increasing risk of body weight loss and other adverse events has not yet been resolved, especially for patients with sarcopenia or frailty. The DAPA-HF and DELIVER trials consistently showed the efficacy and safety of SGLT-2i for HF patients with frailty. However, the Rockwood frailty index that derived from a cumulative deficit model was employed for frailty assessment in these trials, which might not be suitable for the evaluation of physical frailty or sarcopenia alone. There is no fixed consensus on which evaluation tool to use or its cutoff value for the diagnosis and assessment of frailty in HF patients, or which patients can receive SGLT-2i safely. In this review, we summarize the methodology of frailty assessment and discuss the efficacy and safety of SGLT-2i for HF patients with sarcopenia or frailty. |
first_indexed | 2024-03-07T22:25:31Z |
format | Article |
id | doaj.art-3f54e617974d45ef981fbbc65ad26c77 |
institution | Directory Open Access Journal |
issn | 2075-4426 |
language | English |
last_indexed | 2024-03-07T22:25:31Z |
publishDate | 2024-01-01 |
publisher | MDPI AG |
record_format | Article |
series | Journal of Personalized Medicine |
spelling | doaj.art-3f54e617974d45ef981fbbc65ad26c772024-02-23T15:23:40ZengMDPI AGJournal of Personalized Medicine2075-44262024-01-0114214110.3390/jpm14020141The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?Ayami Naito0Yuji Nagatomo1Akane Kawai2Midori Yukino-Iwashita3Ryota Nakazawa4Akira Taruoka5Asako Takefuji6Risako Yasuda7Takumi Toya8Yukinori Ikegami9Nobuyuki Masaki10Yasuo Ido11Takeshi Adachi12Department of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Intensive Care, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Intensive Care, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, JapanSodium-glucose cotransporter-2 inhibitors (SGLT-2is) show cardiovascular protective effects, regardless of the patient’s history of diabetes mellitus (DM). SGLT2is suppressed cardiovascular adverse events in patients with type 2 DM, and furthermore, SGLT-2is reduced the risk of worsening heart failure (HF) events or cardiovascular death in patients with HF. Along with these research findings, SGLT-2is are recommended for patients with HF in the latest guidelines. Despite these benefits, the concern surrounding the increasing risk of body weight loss and other adverse events has not yet been resolved, especially for patients with sarcopenia or frailty. The DAPA-HF and DELIVER trials consistently showed the efficacy and safety of SGLT-2i for HF patients with frailty. However, the Rockwood frailty index that derived from a cumulative deficit model was employed for frailty assessment in these trials, which might not be suitable for the evaluation of physical frailty or sarcopenia alone. There is no fixed consensus on which evaluation tool to use or its cutoff value for the diagnosis and assessment of frailty in HF patients, or which patients can receive SGLT-2i safely. In this review, we summarize the methodology of frailty assessment and discuss the efficacy and safety of SGLT-2i for HF patients with sarcopenia or frailty.https://www.mdpi.com/2075-4426/14/2/141sodium-glucose cotransporter-2 (SGLT-2) inhibitorsheart failurefrailtysarcopenia |
spellingShingle | Ayami Naito Yuji Nagatomo Akane Kawai Midori Yukino-Iwashita Ryota Nakazawa Akira Taruoka Asako Takefuji Risako Yasuda Takumi Toya Yukinori Ikegami Nobuyuki Masaki Yasuo Ido Takeshi Adachi The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? Journal of Personalized Medicine sodium-glucose cotransporter-2 (SGLT-2) inhibitors heart failure frailty sarcopenia |
title | The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? |
title_full | The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? |
title_fullStr | The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? |
title_full_unstemmed | The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? |
title_short | The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword? |
title_sort | safety and efficacy of sodium glucose cotransporter 2 inhibitors for patients with sarcopenia or frailty double edged sword |
topic | sodium-glucose cotransporter-2 (SGLT-2) inhibitors heart failure frailty sarcopenia |
url | https://www.mdpi.com/2075-4426/14/2/141 |
work_keys_str_mv | AT ayaminaito thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yujinagatomo thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT akanekawai thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT midoriyukinoiwashita thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT ryotanakazawa thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT akirataruoka thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT asakotakefuji thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT risakoyasuda thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT takumitoya thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yukinoriikegami thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT nobuyukimasaki thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yasuoido thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT takeshiadachi thesafetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT ayaminaito safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yujinagatomo safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT akanekawai safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT midoriyukinoiwashita safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT ryotanakazawa safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT akirataruoka safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT asakotakefuji safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT risakoyasuda safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT takumitoya safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yukinoriikegami safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT nobuyukimasaki safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT yasuoido safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword AT takeshiadachi safetyandefficacyofsodiumglucosecotransporter2inhibitorsforpatientswithsarcopeniaorfrailtydoubleedgedsword |